GPR119 and Obesity: In various animal models of obesity and type 2 diabetes, orally available, potent, selective, synthetic GPR119 agonists lowered blood glucose without hypoglycemia, slowed diabetes progression, and reduced food intake and body weight [46,52,53,54,55,56,57].